Immune Tolerance and Type 1 Diabetes

Type 1 diabetes (T1D) is a chronic inflammatory disease that develops when the body’s immune system mistakenly attacks the cells that make insulin (called ‘beta cells’).  Insulin allows the body to use energy from food and helps control blood sugar levels, and without it the body cannot function properly. Currently, T1D is treated by life-long insulin replacement, which treats the major symptom but does not cure the underlying disease.

The Immune Tolerance Network (ITN) conducts studies with the goal of identifying treatments that will preserve beta cells and insulin production for individuals recently diagnosed with T1D. 

This page contains a list of ITN's T1D clinical trials that are currently enrolling participants. To see all of ITN's active and completed studies in T1D, please visit For Researchers.

Javascript is required to view this map.

Clinical Trials - Type 1 Diabetes

T1D Extended Study (T1DES)

Principal Investigator:
Linda DiMeglio, MD, MPH, Indiana University and Riley Hospital for Children, Indianapolis, IN

T1DES is a clinical study for people with type 1 diabetes who were previously enrolled in an ITN clinical study.

Learn more:

Preserving Beta-Cell Function with Tocilizumab in New-Onset Type 1 Diabetes (EXTEND)

Principal Investigator:
Carla Greenbaum, MD, Benaroya Research Institute, Seattle, WA

Jane Buckner, MD, Benaroya Research Institute, Seattle, WA

EXTEND is a clinical research study that will test whether a therapy called tocilizumab (Actemra®) can stop the immune system from attacking the remaining beta cells and possibly extend the ability to naturally produce insulin in individuals recently diagnosed with type 1 diabetes.

Learn more: